Softbank Group CORP. Invests $99.15 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Softbank Group CORP. bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,667,491 shares of the company's stock, valued at approximately $99,152,000. Recursion Pharmaceuticals makes up 0.4% of Softbank Group CORP.'s investment portfolio, making the stock its 10th largest holding. Softbank Group CORP. owned about 3.75% of Recursion Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the 4th quarter valued at about $26,000. Private Trust Co. NA bought a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $27,000. Farther Finance Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after buying an additional 1,353 shares in the last quarter. NewEdge Advisors LLC lifted its stake in Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after purchasing an additional 2,387 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 220.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock worth $66,000 after buying an additional 6,758 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Trading Down 1.1%

Shares of NASDAQ RXRX traded down $0.05 during trading on Monday, reaching $4.51. The company had a trading volume of 14,042,347 shares, compared to its average volume of 13,178,861. The stock has a market cap of $1.83 billion, a P/E ratio of -2.95 and a beta of 0.99. The company's fifty day moving average price is $5.34 and its 200-day moving average price is $6.59. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's revenue was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.39) earnings per share. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on RXRX shares. Needham & Company LLC dropped their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Morgan Stanley dropped their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Leerink Partners reduced their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Finally, Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $7.60.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.